Abstract-While Ca 2ϩ influx is essential for activation of the cell cycle machinery, the processes that regulate Ca 2ϩ influx in this context have not been fully elucidated. Electrophysiological and molecular studies have identified multiple Ca 2ϩ
Each primer was searched against BLAST to ensure that it did not match any known gene aside from that for which it was designed, including other family members. All primers were designed for an amplicon length of between 100 to 130 bp, which is optimal for quantitative RT-PCR, with primer melting temperatures of 59°to 61°C and amplicon melting temperatures of 83°to 85°C. Correct amplicon melting temperatures were verified using the ABI dissociation protocol, in which temperatures are increased from 60°to 95°C in half-degree intervals, with quantity of double-stranded DNA checked at each temperature.
RNA was made using a Qiagen RNeasy mini kit. Rat lungs and brains were isolated from 5 adult male Sprague-Dawley rats and pooled. Adult male Sprague-Dawley rats were obtained from Harlan Labs (Indianapolis, Ind) and euthanized with a lethal overdose of pentobarbital in concordance with procedures approved by the University of Colorado Health Sciences Center Laboratory Animal Care and Use Committee. Human lung and brain tissue was purchased from Clontech (Palo Alto, Calif). cDNA was made using Superscript II RT with oligo (dT)12 to 18 primers (both from Invitrogen). For screening gels, PCR was performed in a GeneAmp Sequence Detection System 5700 (Perkin Elmer) using 40 cycles of 95°to 60°PCR with a 10-minute 95°initial soak. For quantitative PCR, the same equipment was used, but the fluorescent indicator Sybergreen was used to allow real-time light detection. 10 Primer efficiency was determined and found to be 100% for all primers. Each measurement was made in triplicate and averaged, with 3 individual replicate experiments used for statistical analysis.
Preparation and Validation of Polyclonal Antibodies
Polyclonal anti-Ca v 3.1 and anti-Ca v 3.2 antibodies were prepared against peptides derived from the deduced T-type channel sequences ␣ 1G /Ca v 3.1: FVCQGEDTRNITNKSDCAEAS; ␣ 1H /Ca v 3.2: YYCEGPDTRNISTKAQCRAAH and immunoaffinity-purified (Bethyl Laboratories). Antisera were immunoabsorbed to the common "DTRNI" peptide to eliminate potential cross-reactivity due to that epitope. Because the antibodies used to detect Ca v 3.1 and Ca v 3.2 had not been previously reported, we performed a series of experiments validating their use. Figure 1 demonstrates the specificity of the antibodies using heterologous expression in HEK cells. Brain was used as a positive control. These examples are representative of 5 replicates and show that the antibodies are selective and have roughly comparable sensitivity. Blocking peptide eliminated immunostaining, showing that the staining is epitope-specific.
Immunoblot
HEK cells were grown in 100 mm dishes to Ϸ70% confluence. Cells were harvested for protein and Western blot run using standard methods. Membranes were probed with 1:200 anti-Ca v 3.1 or -Ca v 3.2. Secondary was 1:1000 donkey anti-rabbit HRP. Similar studies were attempted using cultured human PA SMCs with human brain as a positive control. Although a band for Ca v 3.1 was detected, none was detected for Ca v 3.2 (data not shown).
Immunohistochemistry
Tissue blocks were obtained from the Department of Pathology at the University of Colorado Health Sciences Center under supervision of the institution's Combined Institutional Review Board. Using standard procedures, sections were incubated in primary antibody overnight at 4°C at 1:250 dilution in PBS/4% goat serum/0.1% triton x-100 (PBS). Slides were rinsed and placed in either Alexa Fluor 488 or 594 (Molecular Probes) goat anti-rabbit secondary antibody at a 1:1000 dilution for 1 hour at room temperature. Some slides were also stained for monoclonal anti-SMC ␣-actin (Sigma Chemical) at 1:1000 dilution using the same primary and secondary incubation procedure. Immunocytochemistry followed identical protocols using 8-chamber Falcon Glass Culture slides (Beckton Dickinson). Images were captured with a scanning digital camera (Zeiss) and saved to a PC (Gateway) in TIFF format. For dark field microscopy, images were captured in either the red, green, or blue wavelength and merged in Photoshop CS (Adobe). A standard S-curve was applied to all dark field images to set contrast. Scale was calculated based on the magnification of objectives and transmission lenses and a scale bar placed digitally. For images so noted, a selection of the individual fluorescent channels was magnified digitally to 2 times original size to better show cellular localization.
Cell Culture
Normal human lung PA SMCs obtained from Clonetics/Biowhittaker were cultured in SMC growth media (SmGM-2-bulletkit, Clonetics) with 5% fetal bovine serum (FBS; Gemini) and grown in humidified incubators (Forma Scientific) at 37°C in 5% CO 2 , 16% O 2 , balance N 2 .
RNA Interference
siRNA target finder software (Ambion) was used to design 5 siRNA sequences for inhibition of human Ca v 3.1. 11, 12 Primers for chemical synthesis of siRNA were then constructed by Integrated Data Technologies, Inc and used as described in Ambion's Silencer siRNA construction kit. Primer sequences are listed in the Table. siRNA directed against GAPDH and scrambled siRNA (negative) controls were synthesized using standard templates (Ambion). Figure 5 ).
Cell Counts and Flow Cytometry
PA SMCs, passage 2 to 6, were plated at 3750 cells/cm 2 into 24-well plates and allowed to sit overnight in growth media. Cells were placed into the appropriate treatment group, and cell count and cycle data were collected on days 1, 3, 5, and 7. All treatment groups contained growth media with 5% FBS with the exception of the nonproliferation control, which contained 0.1% FBS. Mean and SEM for six replicates were calculated for cell counts. Cell viability was confirmed by trypan blue exclusion. Cell cycle was determined after 24 hours of treatment by flow cytometry in propidium iodidestained human PA SMCs as previously described. 13 
Statistical Methods
Group means were compared using either Students t test or ANOVA with Fisher post hoc test as appropriate. Data are presented as meanϮSEM with PϽ0.05 accepted as significant.
Results

Electrophysiology
To confirm functional expression of LVA Ca 2ϩ channels in PA SMCs, whole-cell patch clamp was used. Resting E m of PA SMCs was Ϫ48Ϯ4 mV under the experimental conditions. Figure 3 demonstrates macroscopic inward currents. A small, rapidly inactivating inward current with peak current density at Ϫ40mV and a larger, sustained inward current with peak current density at ϩ10mV were apparent when the holding potential was Ϫ90mV. Nifedipine (1 mol/L) eliminated the sustained, but not the transient inward current. Current-voltage relationships compiled when depolarizing from a holding potential of Ϫ90mV demonstrated the two components of the inward current, with a small peak at Ϫ40mV and a larger peak at ϩ10mV. Treatment with nifedipine eliminated the typical L-type current-voltage relationship with peak inward current at ϩ10mV, revealing the smaller transient inward current with peak at Ϫ40mV, typical of T-type currents, whereas mibefradil (1 mol/L) inhibited both components of the inward current. These inward currents are consistent with the presence of both HVA, L-type, and LVA, T-type, Ca 2ϩ channels in PA SMCs. Figure 4A shows a representative gel demonstrating the expression pattern of ␣ 1 subunits in cultured human PA SMCs. As expected, Ca v 1.2, encoding the HVA L-type Ca 2ϩ channel, was detected in PA SMCs. Ca v 3.1 and Ca v 3.2 were also detected, whereas Ca v 3.3 was not readily appreciated. Using real-time PCR, the relative expression levels of the transcripts was estimated. Figure 4B shows the number of PCR cycles required for detection above that required for Effects of siRNA on Proliferation Figure 6 shows the effects of siRNA on Ca v 3.1 expression and proliferation. Figure 6A through 6C demonstrates the high efficiency and efficacy of lipid-mediated delivery of siRNA to human PA SMCs, using fluorescently labeled, prevalidated GAPDH-targeted siRNA. Figure 6D shows the effect of siRNA directed against Ca v 3.1 on protein expression in PA SMCs. This is representative of 3 replicates, all showing that expression of Ca v 3.1 protein was partially suppressed by the siRNA sequence targeting bases 432 to 452 and reduced below the level of detection by Western blot by the remaining 4 siRNA sequences. The effect of Ca v 3.1 siRNA on proliferation is shown in Figure 5E . The 4 siRNAs that blocked Ca v 3.1 protein expression most effectively also inhibited proliferation, whereas control conditions had only a modest nonspecific effect. In addition, the siRNA sequence that had an incomplete effect on Ca v 3.1 protein also had an intermediate effect on proliferation. Figure 7A shows the effect of pharmacological VOCC blockade on proliferation. Five percent serum and 0.1% serum were used as positive and negative controls, respectively. The combined L-and T-type Ca 2ϩ channel blocker mibefradil completely blocked the ability of 5% serum to induce proliferation, whereas the L-type Ca 2ϩ channel blocker diltiazem had no effect when used at a concentration of 10 mol/L (3 times the EC 50 ) and only a modest effect when used at 5 times that concentration (which exceeds the concentration that is selective for L-type channels). 14 Figure 7B shows a summary of FACS analysis of cell cycle, demonstrating that, when compared with diltiazem-treated cells, those treated with either low extracellular Ca 2ϩ or mibefradil showed a much smaller proportion of cells entering S and G 2 /M, and a much higher proportion arrested in G 0 /G 1 . These examples are representative of 3 experiments. For comparing cells arrested in G 0 /G 1 between groups, PϭNS between mibefradil and 0.1% serum, PϽ0.05 between mibefradil and diltiazem, and PϭNS between 10 mol/L diltiazem and 5% serum. No evidence of cell necrosis or apoptosis was detected either grossly or by FACS (as DNA fragmentation).
RT/PCR Analysis of T-Type Channel Gene Expression in PA SMCs and Lung
Effect of Pharmacological VOCC Blockade on Proliferation and Cell Cycle
Discussion
Electrophysiologically, both L-and T-type VOCCs have been identified in vascular SMCs. In the pulmonary circulation, the role of L-type VOCCs in control of vascular tone is well established, and pharmacological L-type blockade results in marked attenuation of hypoxic pulmonary vasoconstriction. 15 In contrast, the role of T-type channels in the regulation of PA tone and structure is less well established. In support of the hypothesis that T-type VOCCs are expressed in the pulmonary circulation, we previously reported that T-type blockade was necessary to eliminate abnormal vasoconstriction in chronically hypoxia rat lungs treated with nitric oxide synthase blockers. 16 We therefore undertook the present study to identify the gene(s) encoding T-type VOCCs and establish their functional significance in PA SMCs.
To confirm the physiological presence of LVA channels, we performed whole-cell patch clamp on early passage, cultured PA SMCs, detecting both LVA and HVA Ca 2ϩ currents. Using RT/PCR, we determined that cultured human PA SMCs expressed mRNA for the T-type ␣-1 subunit genes To identify the cell types in lung expressing Ca v 3.1, we used dual staining for smooth muscle ␣-actin and Ca v 3.1 and localized Ca v 3.1 expression in lung predominantly to SMCs of both large and small pulmonary arteries. In addition, SMCs in small airways expressed Ca v 3.1, suggesting Ca v 3.1 may encode the T-type Ca 2ϩ current previously reported in bronchial SMCs. 19 As with the cell culture studies, Ca v 3.2 protein was not detected in lung tissue.
Our prior studies suggested that T-type channels were important in the remodeled, chronically hypertensive pulmonary circulation, suggesting they could become more prominent in proliferating PA SMCs, possibly playing a role in controlling PA SMC proliferation. In support of that hypothesis, in rat systemic vascular SMCs, the percentage of cells with an electrophysiologically detectable T-type current increased from nondetectable during G 0 to 37% and 90% during G 1 and S-phase, respectively. 20 Consistent with a role for T-type channels in vascular SMC proliferation, mibefradil prevented neointima formation in a carotid balloon injury model in rats. 21 However, when the hypothesis that T-type channels regulate cell proliferation was tested by overexpressing either Ca v 3.1 or Ca v 3.2 in HEK293 (human embryonic kidney) cells, increased Ca 2ϩ influx but no proliferative advantage, as assessed by FACS analysis of cell cycle, was 
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T-type Ca 2؉ Channels Regulate Proliferationseen. 7 More recently, several studies have implicated T-type channels in the proliferation of tumor cells. 22, 23 Thus, the published literature is conflicted on the role of T-type Ca 2ϩ channels in control of proliferation. These conflicting studies could be reconciled, however, if the temporal control of endogenous Ca v 3.x gene expression, rather than constitutive, sustained overexpression, was necessary in SMCs. We addressed that possibility by testing the ability of siRNA directed against Ca v 3.1 to inhibit PA SMC proliferation. The ability of Ca v 3.1 siRNA to block Ca v 3.1 protein expression and macroscopic currents was verified in heterologous expression studies in HEK cells. In PA SMCs, Ca v 3.1-targeted siRNA blocked both channel protein synthesis and proliferation. The nonspecific effect of lipofection (sham group) and GAPDH-targeted siRNA were modest and likely due to time-and dose-dependent toxicity of lipid-nucleotide complexes. In contrast, 4 of 5 Ca v 3.1-targeted siRNAs reduced proliferation by 92% to 98%. The one exception was the sequence that targeted bases 432 to 452. That siRNA sequence was less effective at reducing Ca v 3.1 protein and, consistent with less effective protein knockdown, reduced proliferation by an intermediate value of 65%. Although we did not specifically verify that Ca v 3.1 siRNA did not affect expression of other ion channels, it is highly unlikely that concordant results from 5 distinct siRNA sequences targeted against Ca v 3.1 were the result of unanticipated sequence- , and mibefradil, but was less than that in 5% serum and diltiazem groups (PϽ0.05). Examples (representative of 3 replicates) of FACS sorting for each condition are shown in the remaining panels. DNA fragmentation from apoptosis or necrosis, appearing as a smear to the left of the G 0 /G 1 haploid peak, was not seen.
specific suppression of other ion channel genes. Consistent with a role for Ca v 3.1 in controlling cell cycle, similar effects on proliferation were recently reported using antisense oligonucleotides directed against Ca v 3.1 in tumor cells. 23 Thus, it appears that Ca v 3.1 expression is necessary for serumstimulated proliferation of PA SMCs.
Cell proliferation within normally quiescent vascular smooth muscle cells requires first entry and then progression through the cell cycle toward mitosis. The L-type Ca 2ϩ channel blocker diltiazem had little effect on cell proliferation, whereas the T-type blocker mibefradil completely inhibited proliferation. Consistent with this result mibefradil, but not diltiazem, increased the number of cells arrested in G 0 /G 1 as determined by flow cytometry. These findings, along with lack of evidence of cell necrosis or apoptosis, lend further support to the hypothesis that T-type Ca 2ϩ channel activation is necessary for serum-stimulated PA smooth muscle cell cycle progression and proliferation.
While our studies suggest that T-type Ca 2ϩ channel activation is necessary for proliferation, it is likely that complex signaling processes involving multiple ion channels, including Ca 2ϩ -activated K ϩ (K Ca ) channels and store-operated Ca 2ϩ entry, are required for the full mitogenic response. Some insight into complex vascular signaling involving T-type channels was reported in a recent study of Ca v 3.2 (Ϫ/Ϫ) mice. 24 Although the pulmonary vascular phenotype was not studied, they found significant myocardial fibrosis, associated with coronary artery spasm and impaired NO-mediated coronary artery relaxation. This suggests that in mouse coronary artery, T-type channels, encoded by Ca v 3.2, may be involved in regulating membrane potential, possibly by activating K Ca channels. In a study of rat PA SMCs, Ca 2ϩ entry via store-operated channels (SOCs) encoded by Trp6 was required for PDGF-stimulated proliferation, suggesting a requirement for SOCs as well. 25 These observations could be explained by a model in which Ca 2ϩ entry via T-type channels provides "capacitative calcium entry" in endothelial cells, as was recently described in tumor cells. 22 However, one must be cautious in integrating the results of these studies, as it is highly likely that the role of T-type ␣-1 subunits in regulating membrane potential and cell proliferation is both cell-type and species specific. Thus, studies in each cell type will be required to ascertain the molecular identity of T-type channels and establish their role in controlling proliferation.
In conclusion, these studies establish the existence of the T-type Ca 2ϩ channel ␣-1 subunit Ca v 3.1 in human pulmonary artery SMCs both in vitro and in vivo. RNA interference and pharmacological inhibitor studies provide direct evidence that T-type Ca 2ϩ channels are important regulators of proliferation in pulmonary artery smooth muscle cells. Future studies will be required to determine the mechanisms through which T-type Ca 2ϩ channels regulate cell cycle progression and the relevance of these studies to control of cell cycle and proliferation in other cell types.
Limitations of the Study
We were unable to validate the specificity of Ca v 3.1 siRNA on endogenous Ca v 3.1 expression and function in PA SMCs due to the difficulty in maintaining adequate patch electrode seals in siRNA/lipid complex-treated cells. Therefore, we relied on indirect evidence from heterologous expression studies that the siRNA strategy we used was specific for Ca v 3.1 and did not affect Ca v 3.2 or other signaling pathways. A second limitation is the inability to be certain that the Ca v 3.2 antibody, although apparently specific for Ca v 3.2 and sensitive enough to detect protein expression in brain and heterologous expression studies, was sensitive enough to detect endogenous Ca v 3.2 protein in vascular tissue. Therefore, although our studies strongly support a relationship between Ca v 3.1 expression and control of PA SMC proliferation, they do not completely rule out a contribution of Ca v 3.2 to control of PA SMC proliferation, nor do they rule out a role for Ca v 3.2 in endothelial cell function and paracrine regulation of SMC function, in vivo.
